Novo Nordisk shares fall 5.4% after latest trial results for its next-generation weight loss drug

1 month ago

Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug. 

More Stories

Luka Doncic scores 45 as Lakers win against Mavericks

26 mins ago

Russia-Ukraine war: List of key events, day 1,141

1 hour ago

China consumer prices drop 0.1% in March signaling rising deflationary pressures

3 hours ago

Leave a Reply

Your email address will not be published. Required fields are marked *

You may have missed

Stella: Verstappen is ‘making difference’ in early title battle

26 mins ago

Luka Doncic scores 45 as Lakers win against Mavericks

26 mins ago

Russia-Ukraine war: List of key events, day 1,141

1 hour ago

China consumer prices drop 0.1% in March signaling rising deflationary pressures

3 hours ago

CNBC Daily Open: Euphoria in markets as Trump pauses tariffs — but pauses are temporary

4 hours ago